Thiomorpholino (TMO)-based therapeutics for the treatment of psoriasis and other inflammatory skin diseases
Thiomorpholino oligomers target specific genes in psoriasis to inhibit translation and induce exon skipping, addressing the inadequacies of current treatments by effectively reducing inflammation and symptoms in psoriasis.
WO2026136485A1PCT designated stage Publication Date: 2026-06-25THE REGENTS OF THE UNIVERSITY OF COLORADO
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/060021
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-19
- Filing Date
- 2025-12-17
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Current treatments for psoriasis and other inflammatory skin diseases are inadequate due to adverse effects, treatment resistance, long-term safety concerns, variability in response, and high costs, highlighting the need for more effective therapeutic strategies.
Method used
The use of Thiomorpholino (TMO) oligomer-based therapeutics that target specific genes upregulated in psoriasis, such as IL1RL2, S100A8, and S100A9, to inhibit translation and induce exon skipping, thereby reducing inflammation and keratinocyte proliferation.
Benefits of technology
The TMO oligomers effectively downregulate gene expression, reducing inflammation and psoriasis symptoms by blocking key inflammatory pathways, offering a targeted and safer alternative to existing treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025060021_25062026_PF_FP_ABST
Abstract
Use of antisense thiomorpholino oligonucleotides to treat, prevent, or ameliorate the progression of inflammatory skin diseases or conditions such as psoriasis. Specifically, thiomorpholino¬ containing ASOs that target pre-mRNAs associated with inflammatory skin diseases or conditions such as psoriasis.
Need to check novelty before this filing date? Find Prior Art